Skip to content



Sort by
Page 2 of 2
  1. Content type: Research

    αVβ3, αVβ5 and α5β1 integrins are known to be involved in carcinogenesis and are overexpressed in many types of tumours compared to healthy tissues; thereby they have been selected as promising therapeutic target...

    Authors: Didier J. Colin, James A. H. Inkster, Stéphane Germain and Yann Seimbille

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:16

    Published on:

  2. Content type: Research

    Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible man...

    Authors: Shihong Li, Alexander Schmitz, Hsiaoju Lee and Robert H. Mach

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:15

    Published on:

  3. Content type: Research

    Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in ...

    Authors: M. Meckel, R. Bergmann, M. Miederer and F. Roesch

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:14

    Published on:

  4. Content type: Review

    Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclini...

    Authors: Lei Zhang and Anabella Villalobos

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:13

    Published on:

  5. Content type: Meeting abstracts

    OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets

    Authors: V. Radchenko, J. W. Engle, C. Roy, J. Griswold, M. F. Nortier, E. R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M. E. Fassbender, Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo, Ait-Mohand Samia…

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1(Suppl 1):10

    Published on:

    This article is part of a Supplement: Volume 1 Supplement 1

  6. Content type: Review

    Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure–activity relationship. More recently, tracers have been developed t...

    Authors: Aleksandar Jovalekic, Norman Koglin, Andre Mueller and Andrew W. Stephens

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:11

    Published on:

  7. Content type: Research

    213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide...

    Authors: Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong and Wouter A. P. Breeman

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:9

    Published on:

  8. Content type: Research

    Recently, 44Sc (T1/2 = 3.97 h, Eβ+ av = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this st...

    Authors: Katharina A. Domnanich, Cristina Müller, Renata Farkas, Raffaella M. Schmid, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:8

    Published on:

  9. Content type: Research

    6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (FDOPA) is a frequently used radiopharmaceutical for detecting neuroendocrine and brain tumors and for the differential diagnosis of Parkinson’s disease. To meet the dem...

    Authors: G. Luurtsema, H. H. Boersma, M. Schepers, A. M. T. de Vries, B. Maas, R. Zijlma, E. F. J. de Vries and P. H. Elsinga

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:7

    Published on:

  10. Content type: Research

    Typically, metal-based radiopharmaceuticals are synthesized in aqueous solutions with no or low ethanol content. Labeling yields are defined by temperature, period of labeling, amount of precursor, pH etc. As ...

    Authors: Elisabeth Eppard, Marylaine Pèrez-Malo and Frank Rösch

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:6

    Published on:

  11. Content type: Letter to the Editor

    149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters ...

    Authors: Cristina Müller, Christiaan Vermeulen, Ulli Köster, Karl Johnston, Andreas Türler, Roger Schibli and Nicholas P. van der Meulen

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:5

    Published on:

  12. Content type: Research

    Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. ...

    Authors: Maarten Ooms, Sofie Celen, Ronald De Hoogt, Ilse Lenaerts, Johnny Liebregts, Greet Vanhoof, Xavier Langlois, Andrey Postnov, Michel Koole, Alfons Verbruggen, Koen Van Laere and Guy Bormans

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:3

    Published on:

  13. Content type: Research

    The widespread acceptance and application of 68Ga-PET depends on our ability to develop radiopharmaceuticals that can be prepared in a convenient and suitable manner. A kit-type labelling protocol provides such c...

    Authors: Johanna Seemann, Bradley Waldron, David Parker and Frank Roesch

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:4

    Published on:

  14. Content type: Position paper

    This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of new diagnostic and therapeutic radiopharmaceutica...

    Authors: J. Koziorowski, M. Behe, C. Decristoforo, J. Ballinger, P. Elsinga, V. Ferrari, P. Kolenc Peitl, S. Todde and T. L. Mindt

    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:1

    Published on:

Page 2 of 2

Affiliated with

2017 Journal Metrics

  • Speed
    34 days from submission to first decision
    59 days from submission to acceptance
    22 days from acceptance to publication


Upcoming events


Related websites

Searching for an article? Easily browse the EJNMMI journals on the Nuclear Medicine and Molecular Imaging webportal.